A phase II study of EC17 (folate-hapten conjugate) in patients with progressive metastatic renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2012
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate; GPI 0100; Interferon alpha; Interleukin-2; Keyhole limpet haemocyanin-fluorescein isothiocyanate conjugate
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Endocyte
- 11 Feb 2009 Actual patient numbers (12) added as reported by ClinicalTrials.gov.
- 11 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Feb 2009 Planned end date changed from 1 Jul 2010 to 1 Mar 2009 as reported by ClinicalTrials.gov.